UCB continues to invest in therapies and treatments for Parkinson’s disease, the world’s second most common neurodegenerative disease, affecting six million people worldwide. At present there is a lack of sensitive, objective and quantitative diagnostic measures of relevant functional ability, which are essential for accurate diagnosis and monitoring. To address these challenges, UCB has been supporting the University of Oxford’s QUantification In Parkinsonism (OxQUIP) study, which aims to develop ways of accurately measuring neurological disorders through precise measurement of subtle abnormalities in the timing, speed and coordination of a range of movements in patients at various stages of progression.
In the U.S., UCB also collaborates with multiple research institutions, for example, to better understand the current state of epilepsy and care. In 2020, this included working with Arizona State University (ASU) to launch research into the potential correlation between Social Determinants of Health (SDH) – the conditions in which people are born, grow, live, work and age – and epilepsy health outcomes at a community level. It is hoped that the research findings will help open new doors to supporting patients to access appropriate treatments. UCB is also supporting Indiana University’s School of Nursing in their research into the current state of educational materials on being used in U.S. emergency rooms and epilepsy clinics, to help newly-diagnosed patients better navigate their care and to pave the way for refreshed resources for epilepsy patients that can be tested in emergency department settings.
We embarked on an exciting multi-year collaboration together with Stanford Medicine, as part of our digital business transformation, to develop unique solutions that combine clinical, real-world, and other data sets — along with the required expertise — to identify which patients will respond best and ultimately, deliver better patient outcomes. The first project will focus on hidradenitis suppurativa (HS), also known as acne inversa, an immunological skin disease. UCB and Stanford Medicine plan to explore digital phenotyping, computational discovery of pathogenic mechanisms, and the disease burden and societal experience for people living with severe diseases like HS. By combining UCB and Stanford’s clinical and real-world data and scientific innovation, we can create sustainable value for patients.
We also joined Capture the Fracture, a new collaboration between UCB, the International Osteoporosis Foundation (IOF), Amgen and the University of Oxford to reduce the global public health burden of fractures related to osteoporosis. It is estimated that more than 200 million people worldwide suffer from this degenerative bone condition, resulting in an estimated one fracture every three seconds . Capture the Fracture, originally launched by the IOF, helps to proactively implement post-fracture care (PFC) coordination programs in hospitals and healthcare systems to help patients prevent subsequent fractures. This global partnership will focus on key regions including Asia Pacific, Latin America, the Middle East, and Europe, with the end goal of reducing hip and spine fractures.
2020 saw UCB launch an exciting new global campaign aimed at raising awareness of the unmet needs of women living with chronic inflammatory diseases. World-renowned, Grand Slam tennis champion Caroline Wozniacki has partnered with UCB to be the face of the campaign, entitled Advantage Hers .
As the highest-ranked female athlete known to have been diagnosed with rheumatoid arthritis while still playing professional tennis, Caroline knows first-hand the difficulties of living day-to-day with a chronic disease, and the impact that delays in diagnosis can have. Inspired by Caroline’s own experiences, the Advantage Hers campaign provides women with the tools they need to build their own treatment and management plan together with their healthcare professional and feel empowered to take a more active role in their care.
“I want to connect with as many women with chronic inflammatory diseases around the world as possible. Collectively we can support each other in gaining advantage over our conditions – one small win at a time.”
- 1 https://www.ucb.com/disease-areas/parkinson-s-disease
- 2 Reginster JY, Burlet N. Osteoporosis: A still increasing prevalence. Bone. 2006;38 (2 Suppl 1):S4-S9
- 3 International Osteoporosis Foundation. Capture The Fracture – A global campaign to break the fragility fracture cycle (October 2012). http://share.iofbonehealth.org/WOD/2012/report/WOD12-Report.pdf. Accessed March 11, 2020.